// App-Quantinova.ai

2120 : Safety of Guselkumab in Patients with Psoriatic Disease: An Integrated Analysis of 11 Phase 2/3 Clinical Studies in Psoriasis and Psoriatic Arthritis

Researchers

Presenter

  • Proton Rahman

Principal Investigators

  • Bruce Strober

  • Laura Coates

  • Jenny Yu

  • Katelyn Rowland

  • Evan Leibowitz

  • Megan Miller

  • Alexa Kollmeier

  • Shu Li

  • Yanli Wang

  • Daphne Chan

  • Soumya Chakravarty

  • Ya-Wen Yang

  • May Shawi

  • Mark Lebwohl

Medical Centers

  • Nuffield Department of Orthopaedics, Rheumatology, and Musculoskeletal Sciences,, Oxford University Hospitals NHS Trust, Oxford, UK, Oxford, United Kingdom

  • Janssen Research & Development, LLC, Spring House, PA/San Diego, Spring House, PA/San Diego, CA

  • Janssen Scientific Affairs, Horsham, PA

  • Janssen Research & Development, LLC, Spring House, PA/San Diego, Spring House, PA/San Diego, CA

  • Janssen Research & Development, San Diego, CA

  • Janssen Scientific Affairs, LLC; Drexel University College of Medicine, Horsham; Philadelphia, PA

  • Immunology Global Medical Affairs, Janssen Pharmaceutical Companies of Johnson & Johnson, Horsham, PA, USA

  • Icahn School of Medicine at Mount Sinai, New York, NY

  • Memorial University, St. John's, NF, Canada

Locations

  • United States

  • United Kingdom

  • Canada

Companies

  • JB Medical Ltd.

Study Components

Therapeutic Area

  • Musculoskeletal

  • Autoimmune (AI)

  • Dermatology

Disease

  • Psoriatic arthritis

  • Psoriasis

Biomarkers

  • N/A

Drug/Treatment

  • guselkumab (IV)

Outcome

  • N/A

Study Design

  • Randomized

  • Placebo Control

  • Controlled

Phase

  • II/III

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved